Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.

By |2017-08-23T22:42:28-05:00August 23rd, 2017|Categories: DSF Research Review|Tags: , , |

(Grone B, et al. 2017). Anti-epileptic drug (AED) screening in zebrafish has proven efficient in models of Dravet syndrome due to the lower cost of maintaining fish compared with mouse colonies and rapid reproduction rates. The zebrafish used to study Dravet syndrome carry mutations in scn1lab (a zebrafish version of the human SCN1A gene) and are [...]

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome

By |2017-01-14T18:08:33-05:00January 14th, 2017|Categories: DSF Research Review|Tags: , , , , |

(Griffin, et. al 2017). Building on previous drug screening in a Dravet syndrome model of zebrafish that identified clemizole, a histamine (H1) receptor antagonist, as having anti-epileptic properties, this study sought to further examine the mechanisms of clemizole's action and expand the class of serotonin-acting compounds to include, among others, the FDA-approved drugs lorcaserin (Belviq) and [...]